Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Gilead reported positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis (PBC). The study met its primary endpoint, showing statistically significant composite ALP normalization in patients with inadequately controlled disease (ALP 1-1.67x ULN) compared to placebo after 52 weeks.
Key figures
- Drug Name
- Livdelzi (seladelpar)
- Phase Of Trial
- Phase 3
- Enrollment
- 96
- Trial name
- IDEAL
- Duration weeks
- 52
- Primary endpoint
- Composite ALP normalization (ALP ≤ 1.0x ULN and ≥ 15% decrease from baseline)
- Patient population
- PBC patients with ALP 1-1.67x ULN on or intolerant to UDCA
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.